Pular para o conteúdo
Menu
Mix Vale

National production of the main antiretroviral against HIV begins in Brazil

Carolina Costa
Por 4 min de leitura
Compartilhe
HIV
Foto: Melnikov Dmitriy/ Shutterstock.com

The Oswaldo Cruz Foundation (Fiocruz) finalized, this Wednesday, May 22, the transfer of technology that will allow the full production in Brazil of dolutegravir, the main antiretroviral used to treat HIV. The medicine, essential for more than 770 thousand Brazilians who depend on the Unified Health System (SUS), marks a significant advance in the country’s autonomy in public health.

Publicidade

Completion of cycle strengthens national drug manufacturing

With the completion of the process, Brazil is preparing to supply the SUS with a crucial medicine, reducing dependence on imports. Three batches of dolutegravir have already been manufactured by Fiocruz and have passed rigorous quality tests. The final stage for distribution lies in authorization from the National Health Surveillance Agency (Anvisa), which will allow the medicine to reach patients. The institution reinforced that “the completion of this stage strengthens national production and increases the security of supplying the medicine to the population.”

Publicidade

The details of the technology transfer trajectory

The agreement for the nationalization of dolutegravir was established in 2020, through a partnership between the Institute of Technology in Drugs (Farmanguinhos), a unit of Fiocruz, and ViiV Healthcare. The latter is the company responsible for developing the medicine and belongs to the biopharmaceutical company GSK. Since the beginning of the collaboration, substantial investments have been made to improve the factory, acquire modern equipment, train professionals and structure all the necessary steps so that the production of the medicine can be carried out entirely in Brazilian territory.

Since 2022, even before the transfer was fully completed, Farmanguinhos had already played a vital role in distributing tablets produced by GSK to the SUS, ensuring that treatment was not interrupted. In 2025, the unit also assumed complete laboratory control of the medicine’s quality, a fundamental step to ensure the excellence of the national product. During this period, more than 739 million units were delivered to the public network.

The impact of dolutegravir on patients’ quality of life

Dolutegravir is widely recognized as one of the most effective medicines to combat HIV globally. Its main action consists of blocking the integrase enzyme, preventing the virus from multiplying and, consequently, reducing the patient’s viral load to undetectable levels when treatment is followed correctly. For those living with HIV, this translates into a direct impact on quality of life:

  • Preserves the immune system, keeping the body’s defenses active;
  • Prevents the infection from progressing to AIDS, protecting against opportunistic diseases;
  • Significantly improves the general health and life expectancy of people undergoing treatment;
  • Prevents transmission of the virus to other people when the viral load is undetectable.

This effectiveness not only prolongs life, but also allows people living with HIV to have a life expectancy and quality of life similar to that of the general population.

Why is dolutegravir the leading global choice for HIV treatment?

The World Health Organization (WHO) began recommending dolutegravir as the first choice for the treatment of adults, children, pregnant women and people of childbearing potential since 2019. This universal recommendation is a reflection of its proven efficacy and robust safety profile, making it a mainstay in treatment regimens around the world.

Publicidade

The national production of this medicine reinforces Brazil’s historic stance in relation to public health and universal access. The country, which pioneered the free distribution of antiretrovirals in the 90s, reaffirms its commitment to health sovereignty and ensuring innovative treatments for the population, a fundamental pillar of the SUS.

Next steps in nationalizing HIV treatments

The partnership between Fiocruz and ViiV Healthcare does not end with the production of dolutegravir alone. A new stage of nationalization is already planned, which will focus on manufacturing the combination of dolutegravir and lamivudine. This is another essential medicine in the fight against HIV infection, also distributed free of charge by the SUS, and its domestic production represents another step towards complete Brazilian autonomy in the treatment of high-impact diseases.

Publicidade

Carolina Costa é colaboradora da redação do Mix Vale, portal de notícias com cobertura de Brasil e mundo. Produz conteúdo nas editorias de economia e benefícios, com foco em informação de serviço para o leitor brasileiro. Escreve para o portal desde 2019. Formação: Administração

Notícias relacionadas

Mais lidas

  1. Ciência

    Meteoro no Nordeste: bólido cruza o céu de cinco estados às 21h34 e mobiliza buscas por fragmentos na Paraíba

  2. Caixa Econômica Federal

    Pé-de-Meia paga parcela de R$ 1.000,00 a aprovados no ensino médio de 2026 entre fevereiro e março de 2027

  3. Política

    Com obstrução parcial no intestino, Jair Bolsonaro é internado no hospital DF Star em Brasília

  4. INSS

    Recuperação da senha Gov.br pelo celular exige reconhecimento facial ou código por SMS para o Meu INSS

  5. EUA

    Terremoto em Los Angeles atinge magnitude 4,2 e causa tremores leves em Commerce na madrugada

  6. Matéria Publicitária

    MineMV é o novo jogo grátis de construir com blocos; veja como jogar e liberado para todas as idades

  7. Política

    Regulamentação da escala 5×2 pelo governo encarece cálculo da hora extra a partir de 16 de dezembro

  8. Santa Catarina

    Acidente de trânsito na SC-108 envolve carro e moto e deixa motociclista morto em São Ludgero

  9. Mundo

    Jornalista italiano Corrado Augias morre aos 91 anos; presidente da Itália lamenta a perda

  10. Loterias

    Rendimento de R$ 40 milhões da Mega-Sena 3088 chega a R$ 337 mil por mês no Tesouro Direto